ArticleGut and liver2025

Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study.

Joo Hye Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.